September 23rd 2020
Paul L. Nguyen, MD, discusses the optimal duration of androgen deprivation therapy in patients with high-risk prostate cancer.
Neal D. Shore, MD, FACS, discusses the objective of the phase 3 HERO trial in advanced prostate cancer.
Atish D. Choudhury, MD, PhD, discusses the goal of treating patients with nonmetastatic castration-resistant prostate cancer.
Continuous administration of the novel tubulin inhibitor VERU-111 proved to be safe and demonstrated antitumor activity, evidenced by prostate-specific antigen reductions, objective tumor responses, and durable activity, in men with previously treated metastatic castration-resistant prostate cancer.
September 22nd 2020
Atish D. Choudhury, MD, PhD, compares the safety profiles of antiandrogen agents in nonmetastatic castration-resistant prostate cancer.
Maha Hussain, MD, FACP, FASCO, discusses the safety profile of olaparib as observed in the phase 3 PROfound trial in men with metastatic castration-resistant prostate cancer.
Quoc-Dien Trinh, MD, discusses the challenges of re-establishing standard surgical procedures in patients with prostate cancer following the initial wave of the coronavirus disease 2019 pandemic.
September 21st 2020
Quoc-Dien Trinh, MD, discusses the impact of the coronavirus disease 2019 pandemic on prostate cancer.
Atish D. Choudhury, MD, PhD, discusses the different states of nonmetastatic castration-resistant prostate cancer.
Paul L. Nguyen, MD, discusses future research in high-risk prostate cancer.
